講師
- 籌備委員會成員
- 國際委員會
- 2025 公司展望說明會
- Plenary Session 1 – Global Biotech Development
- Plenary Session 2 – Global Biotech Development
- Plenary Session 3 – The Value of Innovation for a Healthier Taiw
- Session A-1 – New Therapeutic Modalities
- Session A-2 – Gene and Cell Therapies- Advanced Manufacture and
- Session A-3 – AI & Translational Medicine
- Session A-4 – Taiwan BIO Awards-Successful Stories
- Session A-5 – Decision Making on Outsourcing in the Current Chan
- Session A-6 – Innovative Developments and Cross-Disciplinary App
- Session A-7 – Innovative Developments and Cross-Disciplinary App
- Session A-8 – Novel ADC-based Target Therapy
- Session A-9 – Smart HealthCare
- Session A-10 – Exploring the Future of Precision Health in Taiw
- Session A-11 – Special Session: Digital Health
- Session A-12 – Alzheimer’s Disease Forum
- Investment Summit Session B - 1
- Investment Summit Session B - 2
- Regional Collaboration Forum-Thailand
- Regional Collaboration Forum-Malaysia
- Satellite Symposia
- Regional Collaboration Forum-Canada
- Regional Collaboration Forum-Japan
- Regional Collaboration Forum-U.S.A
Grant Hu
Plenary Session 3 – The Value of Innovation for a Healthier Taiwan
Date：23 July
Time：12:00 - 12:05, 13:17 - 13:20 (GMT+8)
Grant Hu
President, IRPMA
CEO & President, Eisai Taiwan
• Joined Eisai on March 1st, 2023
• 27 years sales and marketing experience in three multi-national pharmaceutical companies including J&J, AZ & Merck KGaA
• 6 years’ experience above country including APAC Oncology business lead & Global commercial operations
• Career Journey
– Merck KGaA (2015-2022/ 8 years): Oncology BUD in Taiwan team, Oncology business lead in APAC region & Commercial Operations in Global Oncology Franchise
– AstraZeneca (1998-2014 / 17 years): Different Commercial Role including MR, Brand Manager, Marketing Manager, Sales Manager & Business Unit Director in Primary Care & Specialty Care.
– Jassen-Cliag (1996-1998 / 2 years): Sales Representative in Area HP & Medical Center
Speech title & Synopsis
Opening Remarks & Closing Remarks
.
